Resverlogix Commences Dosing of Patients in Phase 2b COVID-19 Trial
Enrollment and dosing of patients has commenced in a Phase 2b study at a site at the University of Alberta Hospital in Edmonton.
© 2023 Frontier Merchant Capital Group. All Rights Reserved.